Search Results
Found 1 results
510(k) Data Aggregation
(63 days)
ELECSYS LH ASSAY
Immunoassay for the in vitro quantitative determination of human luteinizing hormone in human serum and plasma.
Sandwich principle. Total duration of assay: 18 minutes.
• 1st incubation (9min.): 20 µL of sample, a biotinylated monoclonal LH-specific antibody (75 µL) and a monoclonal LH-specific antibody labeled with a ruthenium complex (75 µL)** react to form a sandwich complex.
• 2nd incubation (9min.): after addition of streptavidin-coated microparticles (30 µL), the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
**Tris(2,2'-bipyridyl)ruthenium(II) complex (Ru(bpy)3)2+)
•The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier (0.4 second read frame).
•Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent bar code.
The provided text describes the performance characteristics of the Elecsys® LH Assay and compares it to a predicate device, the Enzymun-Test® LH. The document acts as a 510(k) Summary, indicating that the study is for regulatory submission to establish substantial equivalence.
Here's a breakdown of the requested information based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance:
The document does not explicitly state "acceptance criteria" for each performance metric but rather presents "Performance Characteristics" for both the new Elecsys® LH and the predicate Enzymun-Test® LH. The implication is that the Elecsys® LH's performance should be comparable to or better than the predicate device for substantial equivalence.
| Feature | Acceptance Criteria (Implied: Comparable to or better than Predicate) | Elecsys® LH Reported Performance |
|---|---|---|
| Precision | Similar %CV values to predicate across low, mid, and high levels. | Low: Within-Run Mean 0.54 mIU/mL, %CV 1.82%; Total Mean 0.54 mIU/mL, %CV 5.17% |
| Mid: Within-Run Mean 9.38 mIU/mL, %CV 1.13%; Total Mean 9.38 mIU/mL, %CV 1.97% | ||
| High: Within-Run Mean 50.72 mIU/mL, %CV 0.81%; Total Mean 50.72 mIU/mL, %CV 1.99% | ||
| Lower Detection Limit | Comparable to or lower than predicate (0.50 mIU/mL). | 0.10 mIU/mL |
| Linearity | Comparable to predicate range (0.5 - 150 mIU/mL) with a deviation of ±10%. | 0.1 - 200 mIU/mL (with a deviation from a linear line of ±10%) |
| Method Comparison | Strong correlation with the predicate device (r value close to 1). | Vs Enzymun-Test® LH: |
| Least Squares: y = 1.00x - 0.199, r = 0.993, SEE = 1.141 | ||
| Passing/Bablok: y = 0.964x + 0.040, r = 0.993, SEE = 0.456 | ||
| Interfering substances | No interference at or above specific concentration limits for bilirubin, hemoglobin, lipemia, biotin, and rheumatoid factor. | No interference at: |
| Bilirubin: 25.0 mg/dL | ||
| Hemoglobin: 1 g/dL | ||
| Lipemia: 1500 mg/dL | ||
| Biotin: 30 ng/mL | ||
| Rheumatoid Factor: 1500 U/mL | ||
| Specificity (Cross-reactivity) | Low or no cross-reactivity with FSH, HCG, TSH, HGH, HPL (e.g., |
Ask a specific question about this device
Page 1 of 1